Exicure, Inc.

E166837

Exicure, Inc. is a biotechnology company specializing in nucleic acid therapeutics based on spherical nucleic acid (SNA) technology.

All labels observed (1)

Label Occurrences
Exicure, Inc. canonical 1

How this entity was disambiguated

Statements (40)

Predicate Object
instanceOf biotechnology company
public company
abbreviation Exicure
aimsToTreat cancer
genetic diseases
neurological diseases
basedOnResearchOf Chad A. Mirkin
businessModel partnering and collaboration strategy
research and development focused
coreTechnology nanoparticle-based nucleic acids
spherical nucleic acids
country United States of America
surface form: United States
develops antisense therapies
gene regulation therapies
oligonucleotide therapeutics
focusesOn genetic disorders
immuno-oncology
neurology
foundedBy Chad A. Mirkin
hasCollaborationWith Allergan
surface form: Allergan (prior to its acquisition by AbbVie)

Ipsen
headquartersLocation Chicago metropolitan area
Skokie, Illinois NERFINISHED
industry biotechnology
listedOn NASDAQ
pipelineIncludes clinical-stage nucleic acid candidates
preclinical nucleic acid candidates
regulatoryStatus subject to U.S. FDA regulation
scientificBasis nanotechnology
nucleic acid chemistry
SNAApplications systemic delivery of nucleic acids
topical delivery of nucleic acids
SNAProperties enhanced cellular uptake
improved tissue penetration
potential for reduced immunogenicity
specializesIn nucleic acid therapeutics
technology spherical nucleic acid technology
tickerSymbol XCUR
usesPlatform spherical nucleic acid (SNA) platform
website https://www.exicuretx.com/

How these facts were elicited

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Chad Mirkin founded Exicure, Inc.